Related Experiment Video

Updated: Dec 20, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.5K

The role of SIRT2 in cancer: A novel therapeutic target

Guangyuan Chen1, Peng Huang2,3, Cong Hu1

  • 1The Second Clinical Medical School, Nanchang University, Nanchang, Jiangxi, China.

International Journal of Cancer
|May 26, 2020
PubMed

Insights

Sirtuin 2 (SIRT2) impacts cancer development, acting as both a tumor promoter and suppressor. Understanding its complex role is key for developing targeted cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Sirtuin 2 (SIRT2) is a protein deacetylase found in human tissues, regulating diverse biological functions.
  • Abnormal SIRT2 expression is linked to various malignant tumors, indicating its involvement in cancer.
  • SIRT2's precise role in tumorigenesis, whether promoting or suppressing, remains debated.

Purpose of the Study:

  • To review the multifaceted role of SIRT2 in tumor evolution.
  • To elucidate the molecular mechanisms underlying SIRT2's functions in cancer.
  • To offer insights for future research and guide targeted therapy development.

Main Methods:

  • Literature review of existing studies on SIRT2 and cancer.
  • Analysis of molecular pathways involving SIRT2 in tumorigenesis.
  • Synthesis of current knowledge on SIRT2's dual role in cancer.

Main Results:

  • SIRT2 exhibits context-dependent functions in cancer, acting as both an oncogene and a tumor suppressor.
  • Evidence suggests SIRT2 influences key cellular processes like cell cycle, DNA repair, and metabolism in tumors.
  • The molecular mechanisms are complex and vary across different cancer types.

Conclusions:

  • SIRT2 is a critical player in cancer progression with a dual role.
  • Further research into SIRT2's mechanisms is essential for clinical applications.
  • Targeting SIRT2 may offer novel therapeutic strategies for malignancies.
Keywords:
SIRT2cancercell cycletumor microenvironment

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.7K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K